Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) with bone involvement requires effective treatments.
• Radium-223 dichloride is a targeted alpha-emitting radioisotope therapy for mCRPC.
• Real-world data on radium-223 efficacy and safety in mCRPC is valuable.

Purpose of the Study:

• To evaluate the clinical characteristics and outcomes of mCRPC patients treated with radium-223 in a real-world setting.
• To compare outcomes based on the number of radium-223 treatment cycles received.
• To identify factors associated with treatment benefit and survival.

Main Methods:

• Retrospective study of 50 mCRPC patients treated with radium-223 (2016-2020).
• Comparison of baseline characteristics between patients receiving 1-3 vs. 4-6 cycles using t-tests and Chi-square.
• Survival analysis using Kaplan-Meier curves; ANOVA for diagnostic variable differences.

Main Results:

• The majority of patients (60%) received 4-6 radium-223 cycles.
• Clinical benefit was observed in 58% of patients.
• Treatment with 4-6 cycles delayed disease progression; higher baseline alkaline phosphatase correlated with longer PFS.

Conclusions:

• Radium-223 is safe and provides clinical benefit for mCRPC patients in a real-world setting.
• Patients with higher pre-treatment alkaline phosphatase levels may experience improved PFS.
• Further research into predictive biomarkers is needed to optimize radium-223 use.